Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP13 – Phase II Study in Primary Aldosteronism
2019-000919-85Phase 2Active
- Sponsor
- Damian Pharma AG
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dexfadrostat in primary aldosteronism (PA), sponsored by Damian Pharma AG. Primary endpoint: Change in plasma aldosterone-to-renin ratio (ARR). Started Feb 2020; status: active.
02
Drugs
dexfadrostat
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on 2019-000919-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000919-85.